Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

NCT03303950 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Anemia
ASXL1 Gene Mutation
EZH2 Gene Mutation
IDH1 Gene Mutation
IDH2 Gene Mutation
Plasma Cell Myeloma
Primary Myelofibrosis
Recurrent Plasma Cell Myeloma
Secondary Myelofibrosis
Thrombocytopenia

Interventions

DRUG: Busulfan
DRUG: Cyclophosphamide
DRUG: Fludarabine
PROCEDURE: Hematopoietic Cell Transplantation
OTHER: Laboratory Biomarker Analysis

Sponsor

University of Utah